Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer
Metrics: PDF 2155 views | HTML 2256 views | ?
Yuzhu Hu1, Ting Yu1, Xiaoxiao Liu1, Yihong He1, Lihong Deng1, Jiajuan Guo1, Yuanqi Hua1, Ting Luo1 and Xiang Gao2
1Department of Head & Neck and Mammary Oncology and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, Laboratory of Molecular Diagnosis of Cancer, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China
2Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, PR China
Xiang Gao, email: [email protected]
Ting Luo, email: [email protected]
Keywords: colorectal cancer; oxaliplatin; fibrin glue; anti-tumor activity; cell proliferation
Received: October 17, 2017 Accepted: December 05, 2017 Published: December 20, 2017
Colorectal cancer is very common worldwide and advanced colorectal cancer exhibited very poor clinical outcome. Oxaliplatin (OXP) is one of the principal chemotherapeutic agents in colorectal cancer treatment presenting impressive anti-tumor ability, limited by adverse effect in clinical practice. Fibrin glue (FG) is a biocompatible formulation made of fibrinogen and thrombin, extensively used in surgery for hemostasis, tissue adhesion and sealing. In this study, FG was innovatively applied as OXP delivery system and results showed enhanced anti-tumor performance in subcutaneous model and abdominal metastasis model of murine colorectal cancer compared with that of OXP used alone. It is revealed that combination of OXP and FG could increase activated CD8+ T cells, reduce regulatory T (Treg) cells and increase interferon-γ (IFN-γ). Furthermore, results showed promoted tumor apoptosis, decreased proliferation and inhibited tumor angiogenesis by OXP and FG combination. No obvious systemic toxicity was observed in this study. Finally, our findings provided basis for promising application of OXP and FG combination in colorectal cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.